1. SIOP-E HR-MBL Hungarian Proposal
Miklós Garami, MD. PhD.
National Coordinator
5th November, 2013
Amsterdam, The Netherlands

2. Active Treatment Maintenance Therapy
Include ABMT th. in HR-MBL group.
We observed increased OS and EFS.
Maintenance Therapy
Relapses remain a problem especially in high risk MBL patients.
We observed most relapses during the 2. year after the beginning of chemotherapy.

3. Maintenance Therapy Metronomic th. (in the 1. yr after active tr.)
topotecan  / topoisomerase inhibitor
vincristine / vinca alkaloid
thalidomide / angiogenesis inhibitor
calcitriol / vitamin D3
Supplementary tr. (in the 2. yr after active tr.)
calcitriol / vitamin D3
astaxanthin / carotenoid
celecoxib / COX-2 inhibitor, NSAID

4. Overall Survival of Low (LR) - and High Risk (HR) Patients 2004-2012
93,8% at 5 yrs
56,5% at 5 yrs
Figure 3.A

5. Event-free Survival of Low (LR) - and High Risk (HR) Patients 2004-2012
86,2% at 5 yrs
41,5% at 5 yrs
Figure 3.B

6. Number of Relapses ( )
Figure 4.

7. Overall Survival (OS) Rates Comparison Treatment Periods: 2004-2006 and 2007-2012
Figure 5.A

8. Event-Free Survival (EFS) Rates Comparison Treatment Periods: 2004-2006 and 2007-2012
Figure 5.B